» Articles » PMID: 26162687

Small Molecule Inhibition of MDM2-p53 Interaction Augments Radiation Response in Human Tumors

Overview
Journal Mol Cancer Ther
Date 2015 Jul 12
PMID 26162687
Citations 28
Authors
Affiliations
Soon will be listed here.
Abstract

MDM2-p53 interaction and downstream signaling affect cellular response to DNA damage. AMG 232 is a potent small molecule inhibitor that blocks the interaction of MDM2 and p53. We examined the capacity of AMG 232 to augment radiation response across a spectrum of human tumor cell lines and xenografts. AMG 232 effectively inhibited proliferation and enhanced radiosensitivity via inhibition of damage repair signaling. Combined AMG 232 and radiation treatment resulted in the accumulation of γH2AX-related DNA damage and induction of senescence with promotion of apoptotic and/or autophagic cell death. Several molecules involved in senescence, autophagy, and apoptosis were specifically modulated following the combined AMG 232/radiation treatment, including FoxM1, ULK-1, DRAM, and BAX. In vivo xenograft studies confirmed more potent antitumor and antiangiogenesis efficacy with combined AMG 232/radiation treatment than treatment with drug or radiation alone. Taken together, these data identify the capacity of AMG 232 to augment radiation response across a variety of tumor types harboring functional p53.

Citing Articles

Evaluation of the antiangiogenic effect of AMG232 in multiple myeloma coculture systems.

Pooraskari Z, Barri Ghazani H, Piri R, Habibi S, Shahidi M Med Oncol. 2025; 42(4):107.

PMID: 40082344 DOI: 10.1007/s12032-025-02659-8.


A Perspective on Therapeutic Targeting Against Ubiquitin Ligases to Stabilize Tumor Suppressor Proteins.

Ganesan I, Kiyokawa H Cancers (Basel). 2025; 17(4).

PMID: 40002221 PMC: 11853300. DOI: 10.3390/cancers17040626.


Modulation of tumor plasticity by senescent cells: Deciphering basic mechanisms and survival pathways to unravel therapeutic options.

Silva A, Bitencourt T, Vargas J, Fraga L, Filippi-Chiela E Genet Mol Biol. 2024; 47Suppl 1(Suppl 1):e20230311.

PMID: 38805699 PMC: 11132560. DOI: 10.1590/1678-4685-GMB-2023-0311.


MDM2 Inhibitors for Cancer Therapy: The Past, Present, and Future.

Wang W, Albadari N, Du Y, Fowler J, Sang H, Xian W Pharmacol Rev. 2024; 76(3):414-453.

PMID: 38697854 PMC: 11068841. DOI: 10.1124/pharmrev.123.001026.


Advancements in MDM2 inhibition: Clinical and pre-clinical investigations of combination therapeutic regimens.

Alaseem A Saudi Pharm J. 2023; 31(10):101790.

PMID: 37818252 PMC: 10561124. DOI: 10.1016/j.jsps.2023.101790.